Prosecution Insights
Last updated: August 06, 2026
Application No. 17/869,367

SYSTEM AND METHOD OF BIOCHEMICAL MOLECULE SYNTHESIS AND DETECTION IN A POINT OF COLLECTION SETTING

Non-Final OA §102§112
Filed
Jul 20, 2022
Priority
Jul 20, 2021 — provisional 63/223,966 +4 more
Examiner
CHUNDURU, SURYAPRABHA
Art Unit
1681
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hui-Ju Tsai
OA Round
3 (Non-Final)
53%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
71%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allowance Rate
386 granted / 723 resolved
-6.6% vs TC avg
Strong +18% interview lift
Without
With
+17.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
59 currently pending
Career history
778
Total Applications
across all art units

Statute-Specific Performance

§101
4.4%
-35.6% vs TC avg
§103
31.3%
-8.7% vs TC avg
§102
29.9%
-10.1% vs TC avg
§112
18.6%
-21.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 723 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION 1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on May 17, 2026 has been entered. Status of the Application 2. Claims 19-21 and 23 are pending under examination. Claim 22 is canceled. Claims 1-18 are previously withdrawn from further consideration as being drawn to nonelected group. The Applicant’s arguments and the amendment have been fully considered and found persuasive in-part foe the following reasons. Claim Rejections - 35 USC § 112-Withdrawn 3. With reference to the rejection of claims under 35 USC 112(b) has been withdrawn in view of the amendment. However, the amendment has been fully considered and found unpersuasive because the claims as filed on 11/11/2025 recite (i.e., shuttled or translocated), which is deleted in the amended claim 19 filed on 5/17/2026, without any text makings. As a formal matter, claims must be presented on a separate sheet, not in continuation with the response to the office action. The claim amendment should show claim text changes with markings (strike-through the deleted limitations and underline the incorporated limitations). See MPEP 714 II.C. Claim Rejections - 35 USC § 102-Maintained 4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 19 and 23 are rejected under 35 U.S.C.102(a)(1) as being anticipated by Jensen et al. (US 2008/0108119). Jensen et al. teach a method of claim 19, for detecting airborne biomolecules, the method comprising: (a) providing a detection system comprising an air pump, an air sampler comprising sample collectors and a movable reaction chamber (chip sites, or sample chambers), a biochemical reagent or buffer (PCR reagents), a heat source (heating electrodes), a detection module (detection electrodes) and an electronic circuit board (programmable unit) (para 0162-0180, 0188-0196, 0103-0104, 0011-0032, 0053, 0064); (b) operating air pump to sample and collecting airborne biomolecules captured by the collectors (para 0175-0180, 0017-0032); (c) introducing the biological reagent and/or buffer to captured biomolecules on the collectors (sample chamber or chip site) (para 0162-0167, 0188-0196, 0017-0032); (d) controlling via the electronic circuit board, moving the movable reaction chamber relative to the heat source, aligning the reaction chamber with a plurality of thermal zones comprising predetermined thermal profile to enable biochemical reagent (PCR reagents including primers, dNTPs, enzymes) to react with the captured biomolecules and produce amplification product (para 0162-0167, 0188-0196, 0017-0032); (e) performing detecting amplification reaction product using the detection module measuring fluorescence signal (para 0179-0183, 0035-0039, 0046). With reference to claim 23, Jensen et al. teach that the electronic circuit board and detection module further process the data, wherein the system further comprises a mobile device operably connected to the electronic circuit board to control or change heat source temperature or and movement of reaction chamber thermal profile to on and off the heat source, detection module comprises at least on temperature sensor and the mobile device collects the data and display the temperature, processing and detection data including amplification detection data, calibration program for thermal control (para 0166-0181, 0199). For all the above the claims are anticipated. Response Arguments: A. The rejection of claims 19 and 21 under 35 USC 102(a)(1) as being anticipated by Castro et al. has been withdrawn in view of the persuasive arguments. B. With reference to the rejection of claims 19-21, 23 under 35 USC 102(a)(1) as being anticipated by Jensen, the Applicant’s arguments have been fully considered and found persuasive in-part for the following reasons. i). With reference to the Applicant’s arguments drawn to no teach of performing nucleic acid sequencing of claim 19 step (e) (ii) by Jensen, the arguments were found unpersuasive because claim 19 step (e) recites performing at least one of (i) or (ii), which do not necessarily require performing both amplification and sequencing. A teaching of detecting amplification reaction product of step (e) (i) as taught by Jensen anticipates the claim 19. Further, with reference to no teaching of integration of sequencing unit at the point of collection by Jensen, the arguments were found unpersuasive because the limitations upon which the Applicant’s arguments depend, are not present in the claims. ii). With reference to the Applicant’s arguments drawn to no teaching of claim 19 step (d), the arguments were found unpersuasive because movement of reaction chamber relative to heat source to sequentially align the chamber with a plurality of temperature zones as required by step (d) is within the scope of the teaching of Jensen et al. because the chamber is physically moved by electronic control to align with different temperature zones. The broader scope of physical movement does not exclude movement of reaction chamber by electronic control. iii). with reference to the Applicant’s arguments drawn to no teaching of sequential reaction and profile comparison of claim 21 by Jensen, the arguments were found persuasive and the rejection of claims 20-21 has been withdrawn. For all the above the rejection of claim 19 and 23 has been maintained and restated. Claim Rejections - 35 USC § 102 5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 19-21 and 23 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Davis et al. (WO 2018/195401). Davis et al. teach a method of claim 19, 21, for detecting airborne biomolecules, the method comprising: (a) providing a detection system comprising an air pump, an air sampler comprising sample collectors (membrane filter) and a movable reaction chamber (cartridge), a biochemical reagent (sorbent), a heat source (thermal sensor), a detection module and an electronic circuit board (page 3, line 4-23, page 8, line 1 to line 7 on page 11); (b) operating air pump to sample and collecting airborne biomolecules captured by the collectors (page 3, line 4-23, page 8, line 1 to line 7 on page 11); (c) introducing the biological reagent and/or buffer to captured biomolecules on the collectors (page 3, line 4-23, page 8, line 1 to line 7 on page 11); (d) controlling via the electronic circuit board, moving the movable reaction chamber relative to the heat source, aligning the reaction chamber with a plurality of thermal zones comprising predetermined thermal profile to enable biochemical reagent to react with the captured biomolecules and produce amplification product and sequencing (page 3, line 4-23, page 8, line 1 to line 7 on page 11, page 21, line 10 to line 20, on page 23); (e) performing detecting amplification reaction and sequencing reads using the detection module measuring fluorescence signal (page 21, line 10 to line 20, on page 23, page 21, line 10 to line 20, on page 23). With reference to claim 20, Davis et al. teach that the detection results are analyzed by a pre-defined statistical model (statistical software), transmitting the analyzed results via the electronic board to remote server for comparative analysis to establish the presence or absence of the airborne biomolecules (page 21, line 10 to line 6 on page 31). With reference to claim 23, Davis et al. teach that the electronic circuit board and detection module further process the data, wherein the system further comprises a mobile device operably connected to the electronic circuit board to control or change heat source temperature or and movement of reaction chamber thermal profile to on and off the heat source, detection module comprises at least on temperature sensor and the mobile device collects the data and display the temperature, processing and detection data including amplification detection data, calibration program for thermal control (page 10, line 15-20, Fig. 1, page 21, line 10 to line 6 on page 31). For all the above the claims are anticipated. Conclusion No claims are allowable. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SURYAPRABHA CHUNDURU whose telephone number is (571)272-0783. The examiner can normally be reached 8.00am-4.30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gary Benzion can be reached at 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Suryaprabha Chunduru Primary Examiner Art Unit 1681 /SURYAPRABHA CHUNDURU/Primary Examiner, Art Unit 1681
Read full office action

Prosecution Timeline

Show 4 earlier events
Oct 27, 2025
Interview Requested
Nov 06, 2025
Applicant Interview (Telephonic)
Nov 11, 2025
Response Filed
Jan 07, 2026
Examiner Interview Summary
Feb 17, 2026
Final Rejection mailed — §102, §112
May 17, 2026
Request for Continued Examination
May 19, 2026
Response after Non-Final Action
Jul 27, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12680131
METHODS AND REAGENTS FOR CHARACTERIZING GENOMIC EDITING, CLONAL EXPANSION, AND ASSOCIATED APPLICATIONS
5y 6m to grant Granted Jul 14, 2026
Patent 12674195
METHODS AND KITS FOR HIGHLY MULTIPLEX SINGLE PRIMER EXTENSION
5y 5m to grant Granted Jul 07, 2026
Patent 12674194
NUCLEIC ACID AMPLIFICATION METHODS
4y 3m to grant Granted Jul 07, 2026
Patent 12668839
METHODS FOR IMPROVING POLYNUCLEOTIDE CLUSTER CLONALITY
6y 6m to grant Granted Jun 30, 2026
Patent 12668825
METHODS FOR MANIPULATING BIOMOLECULES
3y 6m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
53%
Grant Probability
71%
With Interview (+17.8%)
3y 10m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 723 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month